계명대학교 의학도서관 Repository

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Metadata Downloads
Author(s)
Yoon-Koo KangHyung-Don KimJeong Hwan YookYoung-Kyu ParkJong Seok LeeYoung-Woo KimJin Young KimMin-Hee RyuSun Young RhaIk Joo ChungIn-Ho KimSang Cheul OhYoung Soo ParkJae-Ho CheongOh JeongMi Hwa HeoHark Kyun KimChoHyun ParkChang Hak YooSeok Yun KangDae Young ZangYou Jin JangJi Young SulJong Gwang KimBeom Su KimSeung-Hoon BeomJun-Eul HwangSeung Wan RyuMyeong-Cherl KookBaek-Yeol RyooHyunki KimMoon-Won YooNam Su LeeSang Ho LeeSung Hoon Noh
Keimyung Author(s)
Kim, Jin YoungRyu, Seung Wan
Department
Dept. of Internal Medicine (내과학)
Dept. of Surgery (외과학)
Journal Title
J Clin Oncol
Issued Date
2024
Volume
42
Issue
25
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.
The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia.
Keimyung Author(s)(Kor)
김진영
류승완
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
0732-183X
Source
https://ascopubs.org/doi/pdf/10.1200/JCO.23.02167
DOI
10.1200/JCO.23.02167
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45733
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.